JP2022548902A - Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 - Google Patents

Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 Download PDF

Info

Publication number
JP2022548902A
JP2022548902A JP2022517339A JP2022517339A JP2022548902A JP 2022548902 A JP2022548902 A JP 2022548902A JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022548902 A JP2022548902 A JP 2022548902A
Authority
JP
Japan
Prior art keywords
cells
seq
cell
bcma
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517339A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021055349A5 (https=
JP2022548902A5 (https=
Inventor
レズヴァニ、ケイティ
コスタ、ダビド マリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022548902A publication Critical patent/JP2022548902A/ja
Publication of JPWO2021055349A5 publication Critical patent/JPWO2021055349A5/ja
Publication of JP2022548902A5 publication Critical patent/JP2022548902A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2022517339A 2019-09-18 2020-09-15 Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 Pending JP2022548902A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902237P 2019-09-18 2019-09-18
US62/902,237 2019-09-18
PCT/US2020/050864 WO2021055349A1 (en) 2019-09-18 2020-09-15 A method of engineering natural killer-cells to target bcma-positive tumors

Publications (3)

Publication Number Publication Date
JP2022548902A true JP2022548902A (ja) 2022-11-22
JPWO2021055349A5 JPWO2021055349A5 (https=) 2023-09-29
JP2022548902A5 JP2022548902A5 (https=) 2023-09-29

Family

ID=74883668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517339A Pending JP2022548902A (ja) 2019-09-18 2020-09-15 Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法

Country Status (7)

Country Link
US (1) US20220370500A1 (https=)
EP (1) EP4031577A4 (https=)
JP (1) JP2022548902A (https=)
CN (1) CN114729046A (https=)
AR (1) AR119990A1 (https=)
TW (1) TW202124447A (https=)
WO (1) WO2021055349A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
CN118265535A (zh) * 2021-10-20 2024-06-28 得克萨斯大学体系董事会 具有最佳信号传导的car构建体的工程化nk细胞
KR20240099161A (ko) 2021-10-20 2024-06-28 다케다 야쿠힌 고교 가부시키가이샤 Bcma를 표적화하는 조성물 및 이의 사용 방법
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
JP2026512487A (ja) * 2023-04-18 2026-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｃｍａキメラ抗原受容体及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518974A (ja) * 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033110B1 (ru) * 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
EP3283520B1 (en) * 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518974A (ja) * 2015-06-25 2018-07-19 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用

Also Published As

Publication number Publication date
WO2021055349A1 (en) 2021-03-25
EP4031577A4 (en) 2023-12-20
EP4031577A1 (en) 2022-07-27
CN114729046A (zh) 2022-07-08
US20220370500A1 (en) 2022-11-24
TW202124447A (zh) 2021-07-01
AR119990A1 (es) 2022-01-26

Similar Documents

Publication Publication Date Title
JP2022548902A (ja) Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法
JP7690211B2 (ja) Ｃｄ７０陽性腫瘍を標的化するようにナチュラルキラー細胞を操作する方法
US20240325444A1 (en) Chimeric antigen receptor to target trop-2-positive cancers
JP2024521185A (ja) Ｈｌａ－ｇ陽性癌を標的とするキメラ抗原受容体
JP2021522208A (ja) ＣＤ８ａｂおよびクラス１制限Ｔ細胞受容体の強制発現による細胞傷害性ＣＤ８細胞へのＣＤ４ Ｔ細胞の再プログラミング
JP2024514203A (ja) Ｃｄ５陽性がんを標的とするキメラ抗原受容体
JP2023519083A (ja) 細胞がん治療の強化の為のｔ細胞死関連遺伝子８（ｔｄａｇ８）調節
US20240382593A1 (en) Antibody loaded immune cells and methods for use in cancer treatment
JP7773789B2 (ja) 癌の治療のための細胞免疫療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250716